• Modular Learning
  • Resource Database
  • Offerings
    • Partnership Program
    • Seed Fund
    • Modular Learning
    • Resource Database
  • DRIVEN Companies
    DRIVEN Accelerator HubDRIVEN Accelerator Hub
    • Modular Learning
    • Resource Database
    • Offerings
      • Partnership Program
      • Seed Fund
      • Modular Learning
      • Resource Database
    • DRIVEN Companies

      Modular Learning: Operations

      • Home
      • Modular Learning
      • Operations
      Modular LearningOperations
      • Who is the Patient? 4

        • Section1.1
          Introduction
        • Section1.2
          Precision/Personalization, Segmentation, and Incidence/Prevalence
        • Section1.3
          Patient Journey
        • Section1.4
          Expansion/Secondary Indications
      • Standard of Care & Competition 4

        • Section2.1
          Introduction
        • Section2.2
          Unmet Need, Safety, Efficacy, Compliance, Costs
        • Section2.3
          Development Pipeline Analysis/Competitive Intelligence
        • Section2.4
          Competition in Therapeutics (5 forces)
      • Business Model 4

        • Section3.1
          Introduction
        • Section3.2
          Product, Platform or Service
        • Section3.3
          Mission, Vision, Strategy, Tactics, Operations
        • Section3.4
          Who is the Customer?
      • Regulatory 4

        • Section4.1
          Introduction
        • Section4.2
          FDA Introduction
        • Section4.3
          FDA Guidelines
        • Section4.4
          Selecting FDA Consultants
      • Exit/End Goal 4

        • Section5.1
          Introduction
        • Section5.2
          Trade Sales
        • Section5.3
          Sales
        • Section5.4
          Partnerships

        Introduction

        Beginning with the end in mind is always good practice, but it doesn’t have to be slavish; building exit options, including the option not to exit (and to continue operating the business) is good business. Careful planning and execution are required to maximize value capture. Even with a successful therapeutic development in process (or over the finish line), the difference between a base hit and a home run here can be measured in orders of magnitude. We specifically exclude IPOs here as while they do produce liquidity, we believe they should primarily be viewed as a fundraising tactic, not an exit per se.

        Resources

        • Founders Workbench, Startup Exit Masterclass
        • Medium, Startup-grind
        • LifeSciVC

         

        Prev Selecting FDA Consultants
        Next Trade Sales

        driven logo inverted web

        DRIVEN Accelerator Hub   .   info@drivenacceleratorhub.com   .   NIGMS UT2GM13017

        Founded By

        © 2021 DRIVEN Accelerator Hub. All rights reserved.

        Website by RYCO

        Modal title

        Message modal